선천성 근무력 증후군 - 시장 인사이트, 역학 및 시장 예측(2034년)

Congenital Myasthenic Syndromes - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,534,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,301,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,069,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 34,603,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이 보고서는 선천성 근무력 증후군 주요 7개 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)을 조사 분석하여 각 지역의 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 선천성 근무력 증후군 주요 요약

제3장 선천성 근무력 증후군 경쟁 정보 분석

제4장 선천성 근무력 증후군 : 시장 개요

• 선천성 근무력 증후군 전체 시장 점유율 분포(2020년)
• 선천성 근무력 증후군 전체 시장 점유율 분포(2034년)

제5장 선천성 근무력 증후군 : 질환 배경과 개요

• 소개
• 징조와 증상
• 병태생리학
• 위험인자
• 진단

제6장 환자 여정

제7장 선천성 근무력 증후군 역학과 환자 인구

• 역학의 주요 조사 결과
• 가정과 근거 : 주요 7개 시장
• 역학 시나리오 : 주요 7개 시장
  • 주요 7개 시장의 선천성 근무력 증후군 역학 시나리오(2020-2034년)
• 미국의 역학
  • 미국의 선천성 근무력 증후군 역학 시나리오(2020-2034년)
• 유럽 5개국 역학 : 국가별
  • 독일의 역학
  • 프랑스의 역학
  • 이탈리아의 역학
  • 스페인의 역학
  • 영국의 역학
  • 일본의 역학

제8장 치료 알고리즘, 현재 치료, 의료 행위

• 선천성 근무력 증후군 치료와 관리
• 선천성 근무력 증후군 치료 알고리즘

제9장 미충족 수요

제10장 선천성 근무력 증후군 치료의 주요 평가 항목

제11장 출시된 제품

제12장 새로운 치료법

제13장 선천성 근무력 증후군 : 주요 7개 시장 분석

• 주요 조사 결과
• 주요 7개 시장의 선천성 근무력 증후군 시장 규모
• 주요 7개 시장의 선천성 근무력 증후군 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7개 시장 : 시장 전망

• 미국 : 시장 규모
  • 미국의 선천성 근무력 증후군 전체 시장 규모
  • 미국의 선천성 근무력 증후군 시장 규모 : 치료법별
• 유럽 5개국 : 시장 규모와 전망
• 독일의 시장 규모
  • 독일의 선천성 근무력 증후군 전체 시장 규모
  • 독일의 선천성 근무력 증후군 시장 규모 : 치료법별
• 프랑스의 시장 규모
• 이탈리아의 시장 규모
• 스페인의 시장 규모
• 영국의 시장 규모
  • 영국의 선천성 근무력 증후군 전체 시장 규모
  • 영국의 선천성 근무력 증후군 시장 규모 : 치료법별
• 일본 시장 전망
  • 일본의 시장 규모

제16장 선천성 근무력 증후군 액세스와 상환 개요

제17장 KOL의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

ksm

영문 목차

영문목차

DelveInsight's "Congenital Myasthenic Syndromes - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Congenital Myasthenic Syndromes, historical and forecasted epidemiology as well as the Congenital Myasthenic Syndromes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Congenital Myasthenic Syndromes market report provides current treatment practices, emerging drugs, Congenital Myasthenic Syndromes market share of the individual therapies, current and forecasted Congenital Myasthenic Syndromes market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Congenital Myasthenic Syndromes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Congenital Myasthenic Syndromes Disease Understanding and Treatment Algorithm

The DelveInsight Congenital Myasthenic Syndromes market report gives a thorough understanding of the Congenital Myasthenic Syndromes by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Congenital Myasthenic Syndromes.

Treatment

It covers the details of conventional and current medical therapies available in the Congenital Myasthenic Syndromes market for the treatment of the condition. It also provides Congenital Myasthenic Syndromes treatment algorithms and guidelines in the United States, Europe, and Japan.

Congenital Myasthenic Syndromes Epidemiology

The Congenital Myasthenic Syndromes epidemiology division provide insights about historical and current Congenital Myasthenic Syndromes patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Congenital Myasthenic Syndromes epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Congenital Myasthenic Syndromes Epidemiology

The epidemiology segment also provides the Congenital Myasthenic Syndromes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Congenital Myasthenic Syndromes Drug Chapters

Drug chapter segment of the Congenital Myasthenic Syndromes report encloses the detailed analysis of Congenital Myasthenic Syndromes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Congenital Myasthenic Syndromes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Congenital Myasthenic Syndromes treatment.

Congenital Myasthenic Syndromes Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Congenital Myasthenic Syndromes treatment.

Congenital Myasthenic Syndromes Market Outlook

The Congenital Myasthenic Syndromes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Congenital Myasthenic Syndromes market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Congenital Myasthenic Syndromes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Congenital Myasthenic Syndromes market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Congenital Myasthenic Syndromes market in 7MM.

The United States Market Outlook

This section provides the total Congenital Myasthenic Syndromes market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Congenital Myasthenic Syndromes market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Congenital Myasthenic Syndromes market size and market size by therapies in Japan is also mentioned.

Congenital Myasthenic Syndromes Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Congenital Myasthenic Syndromes market or expected to get launched in the market during the study period 2020-2034. The analysis covers Congenital Myasthenic Syndromes market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Congenital Myasthenic Syndromes Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Congenital Myasthenic Syndromes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Congenital Myasthenic Syndromes emerging therapies.

Reimbursement Scenario in Congenital Myasthenic Syndromes

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Congenital Myasthenic Syndromes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Congenital Myasthenic Syndromes market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Congenital Myasthenic Syndromes Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Congenital Myasthenic Syndromes, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Congenital Myasthenic Syndromes epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Congenital Myasthenic Syndromes are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Congenital Myasthenic Syndromes market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Congenital Myasthenic Syndromes market

Report Highlights:

• In the coming years, Congenital Myasthenic Syndromes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Myasthenic Syndromes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Congenital Myasthenic Syndromes. Launch of emerging therapies will significantly impact the Congenital Myasthenic Syndromes market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Congenital Myasthenic Syndromes
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Congenital Myasthenic Syndromes Report Insights

• Patient Population
• Therapeutic Approaches
• Congenital Myasthenic Syndromes Pipeline Analysis
• Congenital Myasthenic Syndromes Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Congenital Myasthenic Syndromes Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Congenital Myasthenic Syndromes Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Congenital Myasthenic Syndromes Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Congenital Myasthenic Syndromes market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Congenital Myasthenic Syndromes total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Congenital Myasthenic Syndromes market size during the forecast period (2024-2034)?
• At what CAGR, the Congenital Myasthenic Syndromes market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Congenital Myasthenic Syndromes market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Congenital Myasthenic Syndromes market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Congenital Myasthenic Syndromes?
• What is the historical Congenital Myasthenic Syndromes patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Congenital Myasthenic Syndromes in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Congenital Myasthenic Syndromes?
• Out of all 7MM countries, which country would have the highest prevalent population of Congenital Myasthenic Syndromes during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Congenital Myasthenic Syndromes treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Congenital Myasthenic Syndromes in the USA, Europe, and Japan?
• What are the Congenital Myasthenic Syndromes marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Congenital Myasthenic Syndromes?
• How many therapies are developed by each company for Congenital Myasthenic Syndromes treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Congenital Myasthenic Syndromes treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Congenital Myasthenic Syndromes therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Congenital Myasthenic Syndromes and their status?
• What are the key designations that have been granted for the emerging therapies for Congenital Myasthenic Syndromes?
• What are the global historical and forecasted market of Congenital Myasthenic Syndromes?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Congenital Myasthenic Syndromes market
• To understand the future market competition in the Congenital Myasthenic Syndromes market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Congenital Myasthenic Syndromes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Congenital Myasthenic Syndromes market
• To understand the future market competition in the Congenital Myasthenic Syndromes market

Table of Contents

1. Key Insights

2. Executive Summary of Congenital Myasthenic Syndromes

3. Competitive Intelligence Analysis for Congenital Myasthenic Syndromes

4. Congenital Myasthenic Syndromes: Market Overview at a Glance

• 4.1. Congenital Myasthenic Syndromes Total Market Share (%) Distribution in 2020
• 4.2. Congenital Myasthenic Syndromes Total Market Share (%) Distribution in 2034

5. Congenital Myasthenic Syndromes: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Congenital Myasthenic Syndromes Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Congenital Myasthenic Syndromes Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Congenital Myasthenic Syndromes Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Congenital Myasthenic Syndromes Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Congenital Myasthenic Syndromes Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Congenital Myasthenic Syndromes Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Congenital Myasthenic Syndromes Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Congenital Myasthenic Syndromes Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Congenital Myasthenic Syndromes Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Congenital Myasthenic Syndromes Treatment and Management
• 8.2. Congenital Myasthenic Syndromes Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Congenital Myasthenic Syndromes Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Congenital Myasthenic Syndromes: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Congenital Myasthenic Syndromes Market Size in 7MM
• 13.3. Congenital Myasthenic Syndromes Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Congenital Myasthenic Syndromes Total Market Size in the United States
  • 15.1.2. Congenital Myasthenic Syndromes Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Congenital Myasthenic Syndromes Total Market Size in Germany
  • 15.3.2. Congenital Myasthenic Syndromes Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Congenital Myasthenic Syndromes Total Market Size in France
  • 15.4.2. Congenital Myasthenic Syndromes Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Congenital Myasthenic Syndromes Total Market Size in Italy
  • 15.5.2. Congenital Myasthenic Syndromes Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Congenital Myasthenic Syndromes Total Market Size in Spain
  • 15.6.2. Congenital Myasthenic Syndromes Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Congenital Myasthenic Syndromes Total Market Size in the United Kingdom
  • 15.7.2. Congenital Myasthenic Syndromes Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Congenital Myasthenic Syndromes Total Market Size in Japan
  • 15.8.3. Congenital Myasthenic Syndromes Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Congenital Myasthenic Syndromes

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료